Can a change in screening and prescribing practice reduce the risk of venous thromboembolism in women taking the combined oral contraceptive pill?

Journal of Family Planning and Reproductive Health Care

Volumn 23, Issue 4, 1998, Pages 112-115

  Mills, Angela ^a   Wilkinson, Chris ^b   Fotherby, Ken ^c  

^a Napolitano and Prof David)   (United Kingdom)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DESOGESTREL; GESTODENE; ORAL CONTRACEPTIVE AGENT;

ARTICLE; CONTRACEPTION; FAMILY HISTORY; FEMALE; HUMAN; MASS SCREENING; ORAL DRUG ADMINISTRATION; RELATIVE; THROMBOPHILIA; VEIN THROMBOSIS;

BIOLOGY; CONTRACEPTION; CONTRACEPTIVE METHODS--SIDE EFFECTS; DEVELOPED COUNTRIES; DISEASES; EMBOLISM; ENGLAND; EUROPE; EXAMINATIONS AND DIAGNOSES; FAMILY PLANNING; MODELS, THEORETICAL; NORTHERN EUROPE; ORAL CONTRACEPTIVES, COMBINED--SIDE EFFECTS; ORAL CONTRACEPTIVES--SIDE EFFECTS; RESEARCH METHODOLOGY; RISK FACTORS; SCREENING; THROMBOEMBOLISM; UNITED KINGDOM; VASCULAR DISEASES;

ADULT; CONTRACEPTIVES, ORAL, COMBINED; FEMALE; HUMANS; MASS SCREENING; MODELS, STATISTICAL; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTIONS, DRUG; RISK; VENOUS THROMBOSIS;

EID: 0031983637     PISSN: 14711893     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Vessey M P. The Jeffcott Lecture, 1989. An overview of the benefits and risks of combined oral contraceptives. In: Mann R D, editor. Oral contraceptives & breast cancer: The implications of the present findings fur informed consent and informed choice. New Jersey, USA: The Parthenon Publishing group, 1989; 121-135.
2. Committee on Safety of Medicines. Combined oral contraceptives and thromboembolism. Letter, October 17, 1995.
3. Bloemenkamp K W M, Rosendaal F R, Helmerhorst F M, et al. Enhancement of factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third generation progestogen. Lancet 1995; 346: 1593-6.
4. Jick H, Jick S, Gurewich V, et al. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestogen components. Lancet 1995; 346: 1589-1593.
5. Spitzer W O, Lewis M, Heinemann L A J, et al. On behalf of the Transnational Research Croup on oral contraceptives and the health of young women. Third generation oral contraceptives and risk. Br Med J 1996; 312: 83-83.
6. World Health Organisation. Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestogens in low dose oral contraceptives on venous thromboembolic disease. Lancet 1995; 346: 1582-1588.
7. Farmer, R D T, Lawrenson, R A, Thompson, C R, et al. Population based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet 1997; 349: 83-88.
8. Farmer R D T, Preston T D. The risk of venous thromboembolism associated with low oestrogen oral contraceptives. Journal of Obstetrics & Gynaecology 1995; 15: 195-200.
9. ICD Coding England and Wales. 1992 annual death rate per million.
10. Pabinger I, Schneider B and the GTH Study Group on Natural Inhibitors. Thrombotic risk of women with hereditary antithrombin III, protein C and protein S deficiency taking oral contraceptives. Thromb Haemost. 1994; 71: 548-552.
11. Mills A M, Wilkinson C L, Bromham D R, et al. Guidelines for prescribing the combined oral contraceptives. Br Med J 1996; 312: 121-122.
12. Pasi K J, Perry D J, Lee C A. Thromboembolism and the combined oral contraceptive pill. Lancet, 1995; 345: 1437.
13. Machin S J, Mackie I J, Guillebaud J. Factor V Leiden mutation, venous thromboembolism and combined oral contraceptive usage. Br J Family Planning 1995; 21: 13-14.
14. Heligren M, Svensson P J, Dahlback B. Resistance to activated protein C as a basis for thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol 1995; 173: 210-213.
15. Bridley F, Wolff M, Laissy, J P, et al. Fatal cerebral thrombosis associated with the factor V Leiden mutation and the use of oral contraceptives. Thromb Haemost 1995; 74: 1582.
16. Dahlback B. Are we ready for factor V Leiden screening?. Lancet 1996; 347: 1346-1347.
17. Rosendaal F R. Oral contraceptives and screening for factor V Leiden. Thromb Haemost 1996; 75: 524-525.
18. Winkler U H. role of screening for vascular disease in pill users: the Hemostatic system. In: Webb, Hannaford, eds. Evidence-guided Prescribing of the Pill. Carnforth Press, 1996.
19. Vandenbroucke J P, Kosteer T, Briet, E, et al. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-1457.
20. Reijnen H B M, Atsma W J. Risk is highest during first months of use. Br Med J 1995; 311: 1639.
21. Vandenbroucke J, van de Meer F, Helmerhorst F, et al. Factor V Leiden: should we screen oral contraceptive users and pregnant women?. Br Med J 1996; 313: 1129-1130.